Abstract
Background. A striking clinical paradox confronts contemporary nephrologists: patients receiving sodium-glucose cotransporter 2 (SGLT-2) inhibitors – among our most advanced therapeutics for diabetes and chronic kidney disease – may require bloodletting, medicine’s most ancient intervention, to manage drug-induced polycythemia.
Objective.To analyze the historical trajectory of bloodletting from universal panacea to evidence-based therapeutic phlebotomy and to demonstrate how physician-historian perspectives inform contemporary clinical decision-making.
Methods. We conducted a comprehensive historical-clinical review examining bloodletting practices across civilizations, analyzing the scientific decline of humoral medicine, and synthesizing current evidence for therapeutic phlebotomy. Primary sources from ancient medical texts through contemporary clinical studies were evaluated to trace the evolution from indiscriminate bloodletting to targeted therapeutic intervention.
Results. Historical analysis reveals bloodletting’s remarkable cultural universality across Egyptian, Greek, Chinese, Islamic, and Ayurvedic medical traditions before systematic 19th-century studies by Pierre-Charles-Alexandre Louis demonstrated its inefficacy in pneumonia. Modern therapeutic phlebotomy emerged as evidence-based treatment for hereditary hemochromatosis, polycythemia vera, and specialized conditions including post-transplant erythrocytosis.
SGLT-2 inhibitors, while providing established cardiovascular and renal benefits, induce secondary polycythemia in susceptible patients in the largest reported series, necessitating therapeutic phlebotomy in selected cases. SGLT-2-induced erythrocytosis is typically reversible, but creates clinical dilemmas when discontinuation compromises heart failure or diabetic nephropathy management.
Conclusions. The physician-historian perspective reveals that medical progress involves refining rather than abandoning traditional practices. The clinical reality that ancient bloodletting now addresses complications from modern molecular therapeutics demonstrates medicine’s cyclical nature and the enduring relevance of historical medical knowledge in solving contemporary clinical challenges.
Keywords: bloodletting, therapeutic phlebotomy, SGLT-2 inhibitors, secondary polycythemia